- When Removing a Big Kidney Stone, Get the Little Ones, Too
- Pandemic Showed Teachers’ Key Role in Spotting Child Abuse
- Health Highlights: Aug. 11, 2022
- Another Study Shows COVID’s Danger to Pregnant Women
- Lung Cancer Can Diminish Sexual Health for Women
- Kids Getting Spinal Surgeries May Cut Back on Opioids
- Biden to Sign Bill That Helps Veterans Exposed to Toxic Burn Pits
- Most Older, Vaccinated Americans Say They’ll Get Updated Booster in Fall: Poll
- AHA News: When Her Smartwatch Indicated She Might Be in AFib, She Thought It Was a Mistake
- FDA Stretches Monkeypox Vaccine Supply by Authorizing Smaller Doses
Brain-Imaging Drug Approved for Alzheimer’s Detection

FRIDAY, Oct. 25Vizamyl (flutemetamol F 18 injection) has been approved by the U.S. Food and Drug Administration for use with positron emission tomography (PET) imaging of the brain to screen adults for signs of Alzheimer’s disease and other forms of dementia.
Dementia — characterized by deteriorating memory, judgment, language and motor skills — has been associated with brain accumulation of a protein called beta amyloid. Vizamyl, combined with a PET scan, can help doctors detect this protein, the FDA said Friday in a news release.
Vizamel, the second diagnostic drug approved for this purpose, was evaluated in clinical studies of 761 people. The injected drug is not meant to predict whether a person will go on to develop Alzheimer’s or other types of dementia, or to evaluate how people may respond to dementia therapies, the FDA warned.
Potential side effects of the drug include allergic-like reaction, becoming flushed, headache, a rise in blood pressure, nausea and dizziness, the agency said.
Vizamyl is produced for GE Healthcare by Medi-Physics Inc., based in Arlington Heights, Ill.
More information
The FDA has more about this approval.
Source: HealthDay